Pharmacokinetics and Dromotropic Activity of Ajmaline in Rats with Hyperthyroidism

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1989 Jan 1

PMID 2924068

Authors

Y Hashimoto

M Yasuhara

A Kamiya

K Okumura

R Hori

Affiliations

Soon will be listed here.

Abstract

1. The pharmacokinetics and the dromotropic action (increased PQ interval) of intravenously administered ajmaline (2 mg kg-1) were studied in hyperthyroid rats with sinus tachycardia. The hyperthyroidism was induced by intraperitoneal injection of 3,5,3'-triiodo-L-thyronine (0.5 mg kg-1) for 4 days. 2. The change in the ajmaline concentration in whole blood could be described by a biexponential equation. The steady state distribution volume of ajmaline decreased from 4.81 l kg-1 in control rats to 3.80 l kg-1 in hyperthyroid rats and the total body blood clearance was slightly higher in hyperthyroid rats than in control rats. 3. Ajmaline exhibited a saturable binding to rat plasma proteins, and one kind of binding site was found in the observed range of concentrations. The binding capacity was 2 fold higher in hyperthyroid rats than in control rats. 4. On the basis of the plasma unbound concentration, ajmaline exhibited an increased negative dromotropic activity in hyperthyroid rats compared with control rats. 5. A positive correlation was found between the pacing rate and the dromotropic action of ajmaline on atrioventricular conduction in isolated perfused hearts. There was no significant difference in the rate-dependence of the effect of ajmaline on the heart between control and hyperthyroid rats. 6. Our findings suggest that the increased dromotropic activity of ajmaline is mainly due to the increased heart rate in hyperthyroid rats.

References

PETTER A . [Various physico-chemical properties of ajmaline, isoajmaline and 17-acetylajmaline]. Arzneimittelforschung. 1974; 24(6):874-6. View

HEISTRACHER P . Mechanism of action of antifibrillatory drugs. Naunyn Schmiedebergs Arch Pharmakol. 1971; 269(2):199-212. DOI: 10.1007/BF01003037. View

Iven H . The pharmacokinetics and organ distribution of ajmaline and quindine in the mouse. Naunyn Schmiedebergs Arch Pharmacol. 1977; 298(1):43-50. DOI: 10.1007/BF00510985. View

Hondeghem L, KATZUNG B . Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta. 1977; 472(3-4):373-98. DOI: 10.1016/0304-4157(77)90003-x. View

Wei J, GENECIN A, Greene H, Achuff S . Coronary spasm with ventricular fibrillation during thyrotoxicosis: response to attaining euthyroid state. Am J Cardiol. 1979; 43(2):335-9. DOI: 10.1016/s0002-9149(79)80023-5. View

Carmeliet E, Zaman M . Comparative effects of lignocaine and lorcainide on conduction in the Langendorff-perfused guinea-pig heart. Cardiovasc Res. 1979; 13(8):439-49. DOI: 10.1093/cvr/13.8.439. View

Myerburg R, Kessler K, KIEM I, Pefkaros K, Conde C, Cooper D . Relationship between plasma levels of procainamide, suppression of premature ventricular complexes and prevention of recurrent ventricular tachycardia. Circulation. 1981; 64(2):280-90. DOI: 10.1161/01.cir.64.2.280. View

Shenfield G . Influence of thyroid dysfunction on drug pharmacokinetics. Clin Pharmacokinet. 1981; 6(4):275-97. DOI: 10.2165/00003088-198106040-00003. View

Feely J, Stevenson I, Crooks J . Altered plasma protein binding of drugs in thyroid disease. Clin Pharmacokinet. 1981; 6(4):298-305. DOI: 10.2165/00003088-198106040-00004. View

10.

Tozer T . Concepts basic to pharmacokinetics. Pharmacol Ther. 1981; 12(1):109-31. DOI: 10.1016/0163-7258(81)90077-2. View

11.

Huang J, Oie S . Effect of altered disopyramide binding on its pharmacologic response in rabbits. J Pharmacol Exp Ther. 1982; 223(2):469-71. View

12.

Follath F, Ganzinger U, Schuetz E . Reliability of antiarrhythmic drug plasma concentration monitoring. Clin Pharmacokinet. 1983; 8(1):63-82. DOI: 10.2165/00003088-198308010-00004. View

13.

Wells P, Feely J, Wilkinson G, Wood A . Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing. Clin Pharmacol Ther. 1983; 33(5):603-8. DOI: 10.1038/clpt.1983.81. View

14.

Hori R, Okumura K, Inui K, Yasuhara M, Yamada K, Sakurai T . Quinidine-induced rise in ajmaline plasma concentration. J Pharm Pharmacol. 1984; 36(3):202-4. DOI: 10.1111/j.2042-7158.1984.tb06942.x. View

15.

Gross G, Lues I . Thyroid-dependent alterations of myocardial adrenoceptors and adrenoceptor-mediated responses in the rat. Naunyn Schmiedebergs Arch Pharmacol. 1985; 329(4):427-39. DOI: 10.1007/BF00496378. View

16.

Hashimoto Y, Hori R, Okumura K, Yasuhara M . Pharmacokinetics and antiarrhythmic activity of ajmaline in rats subjected to coronary artery occlusion. Br J Pharmacol. 1986; 88(1):71-7. PMC: 1917125. DOI: 10.1111/j.1476-5381.1986.tb09472.x. View

17.

Yamada K, Yatsuzuka A, Yasuhara M, Okumura K, Hori R, Sakurai T . Mechanisms of pharmacokinetic interaction between ajmaline and quinidine in rats. J Pharmacobiodyn. 1986; 9(4):347-51. DOI: 10.1248/bpb1978.9.347. View

18.

Vozeh S, Uematsu T, Ritz R, Schmidlin O, Kaufman G, Scholer A . Computer-assisted individualized lidocaine dosage: clinical evaluation and comparison with physician performance. Am Heart J. 1987; 113(4):928-33. DOI: 10.1016/0002-8703(87)90053-6. View

19.

De Rick A, Belpaire F, Dello C, Bogaert M . Influence of enhanced alpha-1-acid glycoprotein concentration on protein binding, pharmacokinetics and antiarrhythmic effect of lidocaine in the dog. J Pharmacol Exp Ther. 1987; 241(1):289-93. View

20.

Yasuhara M, Hashimoto Y, Okumura K, Hori R, Sakurai T, Kawai C . Kinetics of ajmaline disposition and pharmacologic response in beagle dogs. J Pharmacokinet Biopharm. 1987; 15(1):39-55. DOI: 10.1007/BF01062938. View